Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gilotrif

- PMLiVE

AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants

RSV is the leading cause of hospitalisation for infants aged under one year in the US

- PMLiVE

AstraZeneca to stop post-marketing study of Andexxa following early success

The company will now seek full approvals for the bleeding reversal agent in the US and EU

- PMLiVE

Medscape Education is Focusing on Patient Centricity and Education Outcomes at EHA 2023

The Medscape Education team will be on site at the 2023 EHA conference in Frankfurt, Germany to share the outcomes of recent hematology education programs and to advance the discussion on...

Medscape Education Global

- PMLiVE

Amgen’s Lumakras shows promise in phase 3 lung cancer study

The company has also presented results from a study of Lumakras in colorectal cancer

Navigating patients step by step on their clinical trial journey

For clinical trial participants, navigating their way through a study can sometimes seem daunting and complicated. Without the right support, around 30% are likely to drop out [1], resulting in...

Innovative Trials

- PMLiVE

Innovative Trials responds to national recommendations to tackle UK clinical trial decline

Kate Shaw, Founder & CEO, comments on the Lord report of the Lord O’Shaughnessy review into commercial clinical trials in the UK.

Innovative Trials

- PMLiVE

AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

BMS presents positive four-year results for Opdivo combination in lung cancer

NSCLC is the most common type of lung cancer, representing up to 85% of diagnoses

- PMLiVE

Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment

Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

Avalere Health

- PMLiVE

Crick Institute announces new molecular glue discovery to treat different diseases

The £11.2m research investment includes funds from AstraZeneca and the EPSRC

- PMLiVE

Researchers at ICR London discover new nutrient source for cancer growth

Study reveals new findings of dietary changes within pancreatic cancer cells

- PMLiVE

AstraZeneca’s heart failure treatment recommended by NICE for expanded use

More than 550,000 patients have a confirmed heart failure diagnosis in England alone

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links